Pharmaceuticals giant AstraZeneca have said that they are increasing capacity to “ensure the delivery of a globally accessible vaccine.”
The pharma company said they have the capacity to manufacture 1bn doses of the potential coronavirus vaccine, and are planning to start the supply in September.
AstraZeneca said they have taken 400m orders for doses of the vaccine injection, that they are developing with the University of Oxford.
Further deals will be negotiated on capacity “ensure the delivery of a globally accessible vaccine.”
The university said that they are expecting early stage clinical trials results shortly, if these are successful then other trials will take place in other countries.
The pharma giant said they have received over $1bn for the production and delivery of a vaccine, staring in autumn from the, US Biomedical Advanced Research and Development Authority.
Pascal Soriot, chief executive of AstraZeneca, said: “We need to defeat the virus together or it will continue to inflict huge personal suffering and leave long-lasting economic and social scars in every country around the world.
“We are so proud to be collaborating with Oxford University to turn their ground-breaking work into a medicine that can be produced on a global scale.
“We would like to thank the US and UK governments for their substantial support to accelerate the development and production of the vaccine.
“We will do everything in our power to make this vaccine quickly and widely available.”